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 30 
Abstract 31 
Heat-related decreases in cerebral perfusion are partly the result of ventilatory 32 
related reductions in arterial carbon dioxide (CO2) tension. Cerebral perfusion likely 33 
contributes to an individual’s tolerance to a challenge like lower body negative pressure 34 
(LBNP). Thus, increasing cerebral perfusion may prolong LBNP tolerance. This study 35 
tested the hypothesis that a hypercapnia-induced increase in cerebral perfusion 36 
improves LBNP tolerance in hyperthermic individuals.  Eleven individuals (31 ±7 y; 75 37 
±12 kg) underwent passive heat stress (increased intestinal temperature ~1.5°C) 38 
followed by a progressive LBNP challenge to tolerance on two separate days 39 
(randomized).  From 30 mm Hg LBNP, subjects inhaled either (blinded) a hypercapnic 40 
gas mixture (5% CO2, 21% oxygen, balanced nitrogen) or room air (SHAM). LBNP 41 
tolerance was quantified via the cumulative stress index (CSI). Mean middle cerebral 42 
artery blood velocity (MCAvmean,) and end-tidal CO2 (PETCO2,) were also measured.  5% 43 
CO2 inhalation increased PETCO2 at ~40 mm Hg LBNP (by 16 ±4 mmHg) and at LBNP 44 
tolerance (by 18 ±5 mmHg), compared to SHAM (P<0.01).  Subsequently, MCAvmean was 45 
higher in the 5% CO2 trial during ~40 mm Hg LBNP (by 21 ±12 cm.s
-1, ~31%) and at LBNP 46 
tolerance (by 18 ±10 cm.s-1, ~25%) relative to the SHAM (P<0.01).  However, 47 
hypercapnia-induced increases in MCAvmean did not alter LBNP tolerance (5% CO2 CSI: 48 
339 ±155 mm Hg x min; SHAM CSI: 273 ±158 mm Hg x min; P=0.26). These data indicate 49 
that inhaling a hypercapnic gas mixture increases cerebral perfusion during LBNP but 50 
does not improve LBNP tolerance when hyperthermic. 51 
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  54 
Introduction 55 
Heat-induced hyperventilation in humans (14, 16) is associated with high skin 56 
and body core temperatures (Tc in excess of +1.0°C) (6, 12, 17). In normothermic 57 
humans, hyperventilation can also occur during a hypotensive challenge, such as lower 58 
body negative pressure (LBNP) or head-up tilt (30). During a combined hyperthermic 59 
and hypotensive challenge there is a marked increase in ventilation that significantly 60 
reduces end-tidal and arterial carbon dioxide tensions (5, 31). 61 
Cerebral perfusion is profoundly influenced by arterial carbon dioxide tension (3, 62 
19), changing 2-5% per mm Hg of carbon dioxide (32). Increases and decreases in 63 
arterial carbon dioxide tension influence cerebral perfusion via cerebral arteriolar 64 
vasodilation and vasoconstriction, respectively (1). Subsequently, hyperventilation and 65 
related reductions in arterial carbon dioxide tension significantly reduce cerebral 66 
perfusion. During steady-state head-up tilt, cerebral hypoperfusion can be reversed via 67 
CO2 rebreathing, which elevates arterial carbon dioxide tension (30). Furthermore, 68 
inhaling a 5% CO2 gas mixture prevents hypocapnia and improves LBNP tolerance under 69 
normothermic conditions, presumably due to increases in cerebral perfusion (18). 70 
However, an index of cerebral perfusion was not measured in that study, and thus it 71 
remains unknown how cerebral perfusion responded to the hypercapnic stimulus at 72 
LBNP tolerance.  73 
Heat stress significantly reduces an individual’s ability to withstand a 74 
hypotensive challenge (21, 28). While the mechanisms underlying this impaired 75 
tolerance are not fully elucidated, it is clear that hyperthermia reduces cerebral 76 
perfusion at rest (4, 10, 29, 40) and that these reductions are exacerbated during a 77 
hypotensive perturbation (i.e., tilt or stand) (25, 40).  Hyperventilation and related 78 
reductions in PETCO2 are purported to contribute to at least 50% of said reductions in 79 
cerebral perfusion (4, 11, 29, 33). As such, inhaling a hypercapnic gas mixture and 80 
elevating cerebral perfusion should improve tolerance to a hypotensive challenge, given 81 
that cerebral hypoperfusion ultimately results in syncope (38). However, it is unknown if 82 
inhaling a hypercapnic gas mixture and elevating cerebral perfusion improves tolerance 83 
to a hypotensive challenge during heat stress. Such information could have important 84 
ramifications in the treatment of hemorrhagic, hyperthermic individuals, as it may 85 
extend treatment time. Therefore, the purpose of this study was to test the hypothesis 86 
that a hypercapnia-induced increase in cerebral perfusion improves LBNP tolerance in 87 
hyperthermic individuals.   88 
 89 
Methods 90 
Participants 91 
Eleven healthy individuals (8 males, 3 females; 31 ±7 y, 75 ±12 kg, body mass 92 
index, 25 ±3 kg.m2) participated in this study.  Subjects were not taking medications and 93 
were free of any known cardiovascular, metabolic or neurological diseases and were 94 
non-smokers.  Repeated testing was conducted at the same phase of each female 95 
subject’s menstrual cycle, although menstrual cycle phase was not controlled for 96 
between subjects as tolerance to a hyperthermic hypotensive challenge is unaffected by 97 
menstrual cycle phase (28).  Subjects abstained from exercise and alcohol for 24 h prior, 98 
as well as caffeine for 12 h prior to testing.  Written informed consent was obtained 99 
before participation in this study, which was approved by the University of Texas 100 
Southwestern Medical Center at Dallas and Texas Health Presbyterian Hospital Dallas.  101 
All procedures conformed to the standards set by the Declaration of Helsinki. 102 
 103 
Instrumentation 104 
At the beginning of each experimental day, subjects voided their bladder before 105 
nude body mass was recorded.  Urine specific gravity was measured using a digital 106 
refractometer.  Subjects were then dressed in a long-sleeved and legged, two-pieced, 107 
tube-lined perfusion suit (Med-Eng, Ottawa, Canada) enabling the control of skin 108 
temperature and Tc via the temperature of the water perfusing the suit.  Body core 109 
temperature was measured using a telemetry temperature pill swallowed ~2 h before 110 
the onset of data collection (HQ Inc., Palmetto, FL, USA).  Whole-body mean skin 111 
temperature (Tsk) was measured from the electrical average of six thermocouples (37) 112 
fixed to the skin with porous adhesive tape.  Beat-to-beat arterial blood pressure was 113 
measured and reconstructed to the brachial artery via finger cuff 114 
photoplethysmography (Finometer Pro, FMS, Amsterdam, the Netherlands or NexFin 115 
HD, BMEYE B.V, Amsterdam, Netherlands).  Arterial blood pressure was also measured 116 
by auscultation of the brachial artery (Tango, Suntech Medical Instruments, Raleigh, NC, 117 
USA).  Finger arterial pressure was used for data analysis while measures from the 118 
brachial artery and Finometer were used to aid the detection of ensuing syncope.  Mean 119 
blood velocity in the right middle cerebral artery (MCAvmean) served as an index of 120 
cerebral perfusion and was measured using 2 MHz pulsed Doppler ultrasound  121 
(Multiflow, DWL Elektronische Systeme, Singen, Germany).  The Doppler probe was 122 
maintained in position using a commercially available headpiece.  An index of 123 
cerebrovascular conductance (CBVC) was calculated as MCAvmean/mean arterial 124 
pressure (MAP).  Expired air was sampled via a facemask attached to a two-way valve 125 
(Hans Rudolf, inc. Shawnee, KS, USA).  Ventilatory parameters (ventilation, tidal volume, 126 
breathing rate) were measured (in BTPS) using an automated gas analysis system 127 
(TrueOne 2400, Parvo-Medics, Provo, UT, USA), with values recorded over 15-s epochs. 128 
The partial pressure of PETCO2 was sampled from the mask and measured using a
 129 
capnograph (9004 Capnocheck® Plus, Smiths Medical International Ltd, Watford, Herts, 130 
UK).  Heart rate was collected from an electrocardiogram signal (Agilent, Munich, 131 
Germany) interfaced with a cardiotachometer (1000 Hz sampling rate, CWE, Ardmore, 132 
PA, USA).  Thermal and hemodynamic data were acquired continuously at 50 Hz 133 
throughout the experiment (Biopac, Santa Barbara, CA, USA).  134 
 135 
Experimental protocol 136 
Subjects reported to the laboratory on two separate occasions.  At each visit 137 
subjects underwent passive heat stress followed by LBNP to tolerance.  Experimental 138 
trials were at least 3 days apart and were performed at the same time of day.  Following 139 
instrumentation, subjects were positioned in the LBNP box that was sealed at the level 140 
of the iliac crest.  Subjects rested quietly while normothermic water (34°C) circulated 141 
through the suit for at least 30 min. After ~20 min of wearing a face mask connected to 142 
the gas analysis system (ensuring steady-state ventilatory responses), normothermic 143 
baseline thermal, hemodynamic and respiratory measures were obtained for 6 min 144 
while the subject breathed room air.  Subjects were then passively heated by circulating 145 
~49°C water through the suit until Tc increased by ~1.3°C, at which point water 146 
temperature was lowered to ~46°C.  The face mask was reattached 5-10 min before Pre-147 
LBNP measures were obtained.  Progressive LBNP to tolerance was initiated after Tc was 148 
raised ~1.5°C.  Beginning at 20 mm Hg, 3 min stages of LBNP were applied at 10 mm Hg 149 
per stage until the occurrence of syncopal symptoms.  In both trials, subjects inhaled 150 
room air during the 20 mm Hg LBNP stage. In the CO2 trial, subjects inhaled a 151 
hypercapnic gas mixture (5% CO2, 21% oxygen, balanced nitrogen) from the onset of the 152 
30 mm Hg stage through to LBNP tolerance. In the SHAM trial, subjects continued to 153 
breathe room air. Subjects were blinded to the gas mixture they were inhaling, which 154 
was administered in a randomized and counterbalance manner between trials. Criteria 155 
for LBNP test termination were: continued self reporting by the subject of feeling faint 156 
and/or sustained nausea; a rapid and progressive decrease in blood pressure resulting in 157 
sustained systolic blood pressure being less than 80 mm Hg; and/or relative bradycardia 158 
accompanied by narrowing of pulse pressure.  Typically, a combination of the 159 
aforementioned conditions was observed at the cessation of the tolerance test.  The 160 
total time of each test was measured and used to determine a cumulative stress index 161 
(CSI), which was calculated by summing the product of the negative pressure and the 162 
duration at that negative pressure (e.g., 20 mm Hg x 3 min + 30 mmHg × 3 min + 40 163 
mmHg ×3 min, etc.) until test termination (23, 27). 164 
 165 
Data Analysis 166 
In both the SHAM and CO2 trials, 60 s of data were averaged for normothermic 167 
baseline measures.  Pre-LBNP heat stress values were averaged from 60 s of data prior 168 
to the onset of LBNP.  During LBNP, data from the last 60 s at 20 mm Hg and the highest 169 
common LBNP stage completed by each respective participant in both trials (classified 170 
as ‘severe’) were analysed. Hemodynamic LBNP tolerance data were obtained by 171 
averaging responses during the last 10 s prior to cessation of the LBNP challenge due to 172 
syncopal symptoms (26). Ventilatory LBNP tolerance data were obtained by averaging 173 
responses during the last 30 s, thus allowing for inclusion of multiple breaths in this 174 
analysis. 175 
A two-way repeated measures analysis of variance (ANOVA) with main factors of 176 
Time (normothermia, heat stress, 20 mm Hg LBNP, severe LBNP, LBNP tolerance) and 177 
experimental day (SHAM vs. CO2) was used to identify differences in thermal, 178 
hemodynamic and respiratory measures between the SHAM and CO2 trials. Bonferroni-179 
corrected post-hoc tests were used to determine differences when a significant 180 
interaction was identified from the ANOVA.  Paired t-tests were used to identify 181 
differences in CSI, body mass and urine specific gravity. The a priori α level for all 182 
analyses was set at 0.05.  Results are reported as the mean ±S.D.  183 
 184 
Results  185 
 Prior to instrumentation, subjects’ body mass (SHAM, 74.8 ±12.4 kg vs. CO2, 74.5 186 
±12.5 kg; P =0.15) and urine specific gravity (SHAM, 1.014 ±0.006 vs. CO2, 1.011 ±0.005; 187 
P =0.39) were similar between experimental days. Thermal, hemodynamic and 188 
respiratory baseline measures, while subjects were normothermic, were not different 189 
between the two experimental trials (P >0.05, Table 1).  Prior to the onset of LBNP, 190 
passive heat stress caused similar (P >0.05) increases in Tc (~1.3°C) and Tsk (~3.9°C), as 191 
well as similar hemodynamic and respiratory responses (P>0.05; see Table 1).  At the 192 
completion of testing, sweating-induced reductions in body mass were similar (P =0.79) 193 
in both the SHAM and CO2 trials (-1.2 ±0.5 and -1.1 ±0.4 kg, respectively).   194 
LBNP tolerance was similar (P = 0.26) between the two trials, with no difference 195 
in CSI (SHAM: 273 ±158 mm Hg x min vs. CO2: 339 ±155 mm Hg x min, P =0.26), time to 196 
tolerance (SHAM: 514 ±211 s vs. CO2: 604 ±199 s, P = 0.22) or the final LBNP stage 197 
reached (SHAM: 50 ±10 vs. CO2: 50 ±10 mm Hg, P = 0.37).  At 20 mm Hg LBNP, 198 
respiratory and hemodynamic variables were not different between trials (Figures 1, 2 & 199 
3).  Under severe LBNP (~40 mm Hg LBNP), inhaling hypercapnic gas increased PETCO2 200 
(by 16 ±4 mm Hg, P <0.01), ventilation (by 5.2 ±8.2 L.min-1, P =0.03), MCAvmean (by 21 201 
±12 cm.s-1, or 31 ±13%, P <0.01), CBVC (by 0.2 ±0.2 cm.s-1mm Hg-1, P <0.01) and MAP (by 202 
10 ±10 mm Hg, P <0.01), relative to the SHAM trial. At LBNP tolerance the following 203 
variables were higher in the CO2 trial relative to the SHAM trial: PETCO2 (by 18 ±5 mm 204 
Hg, P <0.01), ventilation (by 9.1 ±12.0 L.min-1, P <0.01), tidal volume (by 0.3 ±0.4 L, P 205 
=0.02) and respiratory rate (by 3 ±4 breaths per minute P =0.01).  Likewise, MCAvmean 206 
(by 18 ±10 cm.s-1, or 25 ±13%, P <0.01) and CBVC (by 0.2 ±0.2 cm.s-1mm Hg-1, P <0.01) 207 
were higher in the CO2 trial at LBNP tolerance. Despite those findings, MAP and HR were 208 
not different (P >0.05) between trials at LBNP tolerance. Both trials showed a similar (P 209 
=0.82) relative bradycardia at LBNP tolerance, with HRs decreasing 23 ±12 and 24 ±19 210 
from maximum during the final LBNP stage in the SHAM and CO2 trials respectively.  211 
 212 
Discussion 213 
This is the first study to examine whether elevating cerebral perfusion via 214 
inhalation of a hypercapnic gas mixture improves LBNP tolerance under heat stress 215 
conditions. The novel findings from this study are:  i) inhaling a hypercapnic gas mixture 216 
restores MCAvmean to pre-LBNP values, resulting in cerebral perfusion being elevated at 217 
LBNP tolerance as compared to the control trial (Figure 2), but ii) this higher cerebral 218 
perfusion did not improve LBNP tolerance. 219 
 220 
Restoration of MCAvmean during hyperthermic LBNP 221 
 In the current study, inhaling a hypercapnic gas mixture restored MCAvmean to 222 
pre-LBNP values. Previous studies have shown that in heat-stressed individuals 223 
returning PETCO2 to isocapnic values only partially restores MCAvmean when supine or 224 
seated (4, 11, 33).  Thus, other modulators of cerebral perfusion, such as reductions in 225 
perfusion pressure or an increased sympathetic activity, seemingly contribute to heat-226 
related reductions in MCAvmean (3).  In the current study, heat and LBNP induced 227 
reductions in MCAvmean were essentially ameliorated by inhaling a 5% CO2 gas mixture 228 
and elevating PETCO2. Similarly, clamping PETCO2 during hyperthermic head-up tilt 229 
restores cerebral perfusion to hyperthermic supine values (29).  Furthermore, with 230 
severe heat stress (~+1.8°C Tc) hyperventilation hypocapnia appears the primary 231 
mechanism in reducing cerebral perfusion (29). Thus, in the presence of a strong 232 
hyperventilation stimulus, such as severe hyperthermia and/or a hypotensive challenge, 233 
elevating PETCO2 restores cerebral perfusion.   234 
 235 
Cerebral perfusion, LBNP tolerance and circulatory collapse 236 
Under normothermic conditions, hypocapnia-related cerebral hypoperfusion can 237 
be reversed by rebreathing CO2 (30) and LBNP tolerance is improved by inhaling 5% CO2 238 
(18).  As shown in the present data, inhaling a 5% CO2 gas mixture during hyperthermia 239 
circumvents hyperventilatory hypocapnia and accompanying reductions in cerebral 240 
perfusion. However, this CO2 load did not improve LBNP tolerance, which is surprising 241 
given that hypercapnia significantly elevated cerebral perfusion and CBVC. Indeed, 242 
relative to pre-LBNP, in the SHAM trial LBNP tolerance was accompanied by a 27 ±9% 243 
reduction in MCAvmean, whereas in the CO2 trial, LBNP tolerance was accompanied by 244 
just a 10 ±10% reduction in MCAvmean. Despite these differences, similar decreases in 245 
MAP and HR occurred in both the CO2 and SHAM trials, confirming that LBNP-induced 246 
circulatory collapse was achieved under both conditions. These findings indicate that 247 
inhaling 5% CO2 dissociated cerebral perfusion from circulatory collapse during 248 
simulated hemorrhage in hyperthermic individuals, demonstrating that cerebral 249 
hypoperfusion is not requisite for cardiovascular collapse. 250 
Cardiovascular (or circulatory) collapse occurs when cardiac output falls to 251 
critically low levels, often in concert with reduced sympathetic activity (8).  This, 252 
accompanied by increases in cardiac parasympathetic activity, results in a sudden 253 
bradycardia and/or decrease in systolic blood pressure (7, 8). In the current study, there 254 
were similar decreases in MAP and HR in both the CO2 and SHAM trial at LBNP 255 
tolerance. Thus, both trials exhibited typical hallmarks of cardiovascular collapse 256 
(sympathoinhibition and vagal activation) that resulted in a similar reduction in MAP 257 
without a corresponding physiologically relevant reduction in MCAvmean in the CO2 trial. 258 
Interestingly, the current data indicate that cardiac vagal discharge and 259 
accompanying bradycardia that typically preceding syncope may be unrelated to 260 
cerebral perfusion under hyperthermic conditions. This is perhaps not surprising given 261 
that this bradycardia has been proposed to be mediated by reductions in ventricular 262 
volumes and subsequent activation of cardiac vagal afferents (9). Furthermore, other 263 
studies have shown a dissociation between cerebral perfusion and LBNP tolerance in 264 
normothermic individuals; that is LBNP intolerance persisted despite elevated cerebral 265 
perfusion (20), while hyperventilation-induced reductions in cerebral perfusion during 266 
LBNP failed to initiate premature presyncope or hemodynamic collapse (23). These and 267 
the present findings support the hypothesis that cerebral perfusion may not always be 268 
the primary factor leading to intolerance to a hypotensive challenge. That cerebral 269 
perfusion can essentially be maintained in the face of profound central hypovolemia 270 
could have important ramifications for trauma and hemorrhage treatment; although, it 271 
is unclear whether CO2-induced increases in cerebral perfusion would have prolonged 272 
consciousness should the trial have continued to the point of unconsciousness. Indeed, 273 
in the current study cardiovascular measures were the primary objective criteria used to 274 
determine LBNP cessation.  275 
  276 
Ventilation and hyperthermic LBNP 277 
Heat stress often causes hyperventilation and related hypocapnia, evidenced in 278 
the present investigation by elevating ventilation ~3.1 L.min-1 and decreasing PETCO2 ~4 279 
mm Hg in both the SHAM and CO2 trials prior to LBNP. This heat-induced 280 
hyperventilation is similar (13) or lower (6, 12) than that reported in other studies. As 281 
anticipated (5, 31), ventilation continued to increase and PETCO2 to decrease with 282 
progressive LBNP in the SHAM trial.  283 
Hypercapnia caused further increases in ventilation in the CO2 trial relative to 284 
that which occurred with the SHAM trial.  Similar hypercapnic ventilatory responses 285 
have been shown during normothermic LBNP (40 mm Hg) (22).  Such increases in 286 
ventilation, and particularly tidal volume, may aid venous return and subsequently help 287 
maintain cardiac output via the respiratory pump (2, 36), though it is unknown whether 288 
this occurs during hyperthermia. Certainly, the maintenance of MAP during severe LBNP 289 
in the CO2 trial, versus the gradual reduction in MAP during the SHAM trial, suggests 290 
that larger increase in ventilation during the CO2 trial augments venous return. 291 
However, despite this, hypercapnia did not improve LBNP tolerance under heat stress 292 
conditions, thereby indicating that any increases in cardiac output due to increased tidal 293 
volume was insufficient to improve tolerance.  294 
 295 
Technological considerations 296 
Transcranial Doppler was used to measure blood velocity in the middle cerebral 297 
artery. This approach has been used as an index of cerebral blood flow, as this artery 298 
supplies ~80% of the blood flow received by each cerebral hemisphere (24) and its 299 
diameter is reported to not change during moderate CO2 and blood pressure 300 
perturbations (15, 35). However, recent studies have shown that the regulation of blood 301 
flow differs between the brainstem and cortex with the brainstem being less sensitive to 302 
hypocapnia (34, 39). Although speculative, it may be that hypercapnia-induced increases 303 
in MCAvmean during hyperthermic LBNP do not reflect comparable increases in blood 304 
flow to other areas of the brain, namely the brainstem.  It is also important to consider 305 
potential differences in cerebral hemodynamics during an LBNP challenge versus the 306 
upright posture. Orthostatic-induced syncope is reported to occur upon an ~50% 307 
reduction in MCAvmean (38). However, the current study indicates that presyncopal 308 
symptoms can occur without a meaningful reduction in MCAvmean during LBNP. 309 
 310 
Implications 311 
  The current study demonstrates that the administration of 5% CO2 could be 312 
advantageous in the maintenance of cerebral perfusion during a hypotensive challenge, 313 
attenuating the reduction in cerebral perfusion even at circulatory collapse. These 314 
findings could have implications for the treatment of individuals suffering from a 315 
hemorrhagic injury, when maintenance of brain perfusion becomes paramount. Though, 316 
it should be noted that the tracking of the MCAvmean will not necessarily enable the 317 
prediction or identification of circulatory collapse or shock, at least in heat stressed 318 
individuals.  319 
 320 
Conclusions 321 
 During hyperthermia, inhaling a hypercapnic gas mixture and circumventing 322 
hyperventilation-induced hypocapnia does not improve LBNP tolerance, despite 323 
restoring cerebral perfusion. This disassociation between cerebral perfusion and 324 
systemic circulatory responses during central hypovolemia indicates that cerebral 325 
perfusion may be maintained in the face of a severe hypotensive challenge, even to the 326 
point of circulatory collapse.  327 
 328 
 329 
 330 
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450 
Table 1: Baseline thermal, hemodynamic and respiratory measures during normothermia and heat stress (immediately prior to 451 
lower body negative pressure, Pre-LBNP) for both the control (SHAM) and CO2 trials. 452 
 Normothermia Heat stress (Pre-LBNP) 
 Baseline SHAM Baseline CO2 Baseline SHAM Baseline CO2 
Tc (°C) 36.8 ±0.3 36.7 ±0.3 38.1 ±0.3 # 38.0 ±0.2 # 
Tsk (°C) 34.5 ±0.3 34.4 ±0.5 38.4 ±0.5 # 38.3 ±0.6 # 
MCAvmean (cm·s
-1 ) 65 ±17 66 ±12 55 ±15 # 57 ±14 # 
CBVC (cm·s−1 mm Hg−1) 0.8 ±0.2 0.8 ±0.2 0.7 ±0.2 0.7 ±0.2 
PETCO2 (mm Hg) 41 ±3 41 ±3 36 ±5 # 38 ±3 # 
Ventilation BTPS (L.min-1) 8.1 ±2.2 8.0 ±3.7 11.0 ±3.8 # 9.9 ±4.3 # 
Tidal volume (L) 0.6 ±0.2 0.6 ±0.2 0.9 ±0.4 # 0.9 ±0.4 # 
Respiratory rate  14 ±2 14 ±4 15 ±5 13 ±5 
MAP (mm Hg) 86 ±10 83 ±10 80 ±7 79 ±6 
HR (bpm) 57 ±8 58 ±8 96 ±14 # 95 ±12 # 
 Tc , body core temperature; Tsk, mean skin temperature; MCAvmean, middle cerebral artery velocity; CBVC, cerebrovascular 453 
conductance; PETCO2, end-tidal carbon dioxide; MAP, mean arterial pressure; HR, heart rate. # Significantly different from 454 
normothermic baseline, P <0.05.455 
Figure 1: Ventilatory measures (BTPS) during both heat stress lower body negative 456 
pressure (LBNP) tests where subjects inhaled either a hypercapnic gas mixture or room 457 
air (SHAM). PETCO2: end-tidal partial pressure of carbon dioxide. ‡ Significantly different 458 
from SHAM trial (P <0.05); 1 Significantly different from 0 mm Hg (P <0.05); 2 459 
Significantly different from 20 mm Hg (P <0.05); 3 Significantly different from severe 460 
LBNP (P <0.05). 461 
Figure 2: Cerebrovascular measures during both heat stress lower body negative 462 
pressure (LBNP) tests where subjects inhaled either a hypercapnic gas mixture or room 463 
air (SHAM). MCAvmean: mean middle cerebral artery blood velocity; CBVC: 464 
cerebrovascular conductance.  ‡ Significantly different from SHAM trial (P <0.05); 1 465 
Significantly different from 0 mm Hg (P <0.05); 2 Significantly different from 20 mm Hg (P 466 
<0.05).   467 
Figure 3: Mean arterial pressure (MAP) and heart rate (HR) measures during both heat 468 
stress lower body negative pressure (LBNP) tests where subjects inhaled either a 469 
hypercapnic gas mixture or room air (SHAM). ‡ Significantly different from SHAM trial (P 470 
<0.05); 1 Significantly different from 0 mm Hg (P <0.05); 2 Significantly different from 20 471 
mm Hg (P <0.05); 3 Significantly different from severe LBNP (P <0.05). 472 
 473 
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